Table 2.
Circulating miRNAs of highest expression in CLL patients (fold change compared to the reference sample)
| miRNA | Number | Mean | Median | Minimum | Maximum | Std. deviation |
|---|---|---|---|---|---|---|
| miR-34a-5p | 22 | 6.647689 | 1.862355 | 0.000000 | 61.91293 | 14.16198 |
| miR-31-5p | 22 | 4.474437 | 1.929808 | 0.000000 | 26.27631 | 7.50078 |
| miR-155-5p | 22 | 3.657947 | 1.542619 | 0.000000 | 21.42856 | 4.858174 |
| miR-150-5p | 22 | 1.519764 | 0.862124 | 0.006600 | 8.65041 | 1.952950 |
| miR-15a-3p | 22 | 1.433167 | 0.604238 | 0.000000 | 12.88144 | 2.701575 |
| miR-29a-3p | 22 | 1.244012 | 0.961733 | 0.045252 | 5.97998 | 1.32323 |
| miR-574-3p | 22 | 0.968155 | 0.299874 | 0.028972 | 6.78702 | 1.58355 |
| miR-29c-3p | 22 | 0.929145 | 0.645566 | 0.009438 | 4.14237 | 0.97865 |
Expression values were presented as the logarithm of R to the base 2, where R was calculated as follows: R = 2−ΔΔCt, ΔΔCt = ΔCt of CLL patient − ΔCt of normal individuals, every ΔCt = Ct of miRNA examined − Ct of endogenous control, 1 − mean expression in pooled miRNAs of normal individuals